In focus: Non-small cell lung cancer: E1505

Clinical Advances in Hematology and Oncology

Volumn 5, Issue 3, 2007, Pages 206-207

  Wakelee, Heather ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE;

ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SURGERY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT DURATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34247542119     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350: 351-360.
2. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352: 2589-2597.
3. Strauss GM, Herndon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of cancer and leukemia group B (CALGB) Protocol 9633. J Clin Oncol. 2004;22: 621s. Abstract 7019.
4. Douillard JY, Rosell R, Delena M, et al. ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association. J Clin Oncol. 2005;23: 624s. Abstract 7013.
5. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
6. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153-156.
7. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol. 2004;22:785-794.
8. Mattern J, Koomagi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer. 1996;73:931-934.
9. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10:145-147.
10. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;335;2542-2550.